The BRIDGE-DS Study: Improved Glycemic Control and Renal Function in Type 2 Diabetes Mellitus Patients Using the Fixed-Dose Combination of Dapagliflozin and Sitagliptin
Journal of Endocrinology and Metabolism · 2025
DOI: 10.14740/jem1055 ↗At a glance
Journal article in Journal of Endocrinology and Metabolism, 2025. Written by Animesh Maiti and 15 co-authors. The full text is freely available (open access, CC BY-NC 4.0).
Topics: Diabetes mellitus
Abstract (original language)
Background
Chronic kidney disease (CKD) is characterized by persistent or intermittent albuminuria and a declining glomerular filtration rate (GFR). CKD affects 20-40% of patients with diabetes globally, with significant impacts on health outcomes and healthcare costs. Type 2 diabetes mellitus (T2DM) patients with poor glycemic control are at higher risk of developing CKD, leading to severe complications, including end-stage kidney disease (ESRD).
Methods
A retrospective, multicenter, observational study was conducted using a case-based questionnaire survey to collect data anonymously from diabetologists and endocrinologists across India. The study included T2DM patients with CKD who received a fixed-dose combination (FDC) therapy of dapagliflozin and sitagliptin (D/S). Data were collected digitally and analyzed using SPSS® Version 23.0 software.
Results
Data from 510 patients were collected, comprising 67.6% males and 32.4% females. The median age of the patient cohort was 56 years. After 3 months of FDC D/S treatment, significant reductions in glycated hemoglobin (HbA1c) levels from 9.00% to 7.50%, along with reductions in fasting plasma glucose (FPG) and post-prandial glucose (PPG) levels, were noted. Serum creatinine levels decreased by 0.37 mg/dL, while estimated glomerular filtration rate (eGFR) values improved from 83.83 to 84.00 mL/min/1.73 m2, indicating a potential improvement in renal function. Adverse events (AEs) included urinary tract infections (UTIs), dehydration, hypoglycemia, and genital mycotic infections.
Conclusion
The study demonstrated that FDC D/S therapy is effective and safe for the management of T2DM and CKD, showing significant improvements in glycemic control and renal function. The combination therapy resulted in notable reductions in HbA1c, FPG, and PPG, along with improved eGFR values, underscoring its renoprotective effects. Despite some AEs, the findings support the use of D/S in combination therapy for patients with T2DM and CKD. However, further research is required to explore the long-term effects and optimal dosing strategies of this drug combination.
Cite
APA
Maiti, A., Pandey, A. K., Kale, S., Mukherjee, T., Biswas, A., Pal, S. K., A, R., Vignesh, J., Navin, R., Nelakuditi, L. K., Gillurkar, C., Bandyopadhyaya, B., Detroja, N., Kesarkar, R. N., Prasad, A., & Pednekar, A. (2025). The BRIDGE-DS Study: Improved Glycemic Control and Renal Function in Type 2 Diabetes Mellitus Patients Using the Fixed-Dose Combination of Dapagliflozin and Sitagliptin. Journal of Endocrinology and Metabolism. https://doi.org/10.14740/jem1055
Vancouver
Maiti A, Pandey AK, Kale S, Mukherjee T, Biswas A, Pal SK, et al. The BRIDGE-DS Study: Improved Glycemic Control and Renal Function in Type 2 Diabetes Mellitus Patients Using the Fixed-Dose Combination of Dapagliflozin and Sitagliptin. Journal of Endocrinology and Metabolism. 2025. doi:10.14740/jem1055
BibTeX
@article{Maiti2025,
author = {Maiti, Animesh and Pandey, Arun Kumar and Kale, Shailja and Mukherjee, Tirthankar and Biswas, Amitabh and Pal, Salil Kumar and A, Ramanan and Vignesh, J.P. and Navin, R. and Nelakuditi, Lakshmana Kumar and Gillurkar, Chandrashekhar and Bandyopadhyaya, Biplab and Detroja, Nilesh and Kesarkar, Rohan Narayan and Prasad, Ashish and Pednekar, Abhijit},
title = {The BRIDGE-DS Study: Improved Glycemic Control and Renal Function in Type 2 Diabetes Mellitus Patients Using the Fixed-Dose Combination of Dapagliflozin and Sitagliptin},
journal = {Journal of Endocrinology and Metabolism},
year = {2025},
doi = {10.14740/jem1055}
}
EUVIMED